Q-omics provides the consensus-scored CT62 profile across patient tissues and cancer cell-line models. CT62 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CT62 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CT62 RNA expression shows 12,717 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where CT62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT62 survival associations across molecular data types. CT62 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT62 RNA expression–survival associations across cancer types. High CT62 expression shows unfavorable associations in KIRP, KIRC and DLBC, but favorable associations in ESCA, BRCA and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CT62 RNA expression.
This table summarizes CT62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CT62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT62 shows lower tumor expression in KIRC, COAD, KIRP and LUAD and higher tumor expression in HNSC and KICH. The KIRC box plot shows higher CT62 RNA expression in normal versus tumor tissue (log2 FC = −0.161, t-test p < 0.001).
This table shows molecular features associated with CT62 in patient tissues and cancer cell lines. In patient samples, CT62 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CT62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
